Portfolio Fund No.2

Fund No.2 is a special purpose vehicle managed by Zoic Capital. Its investment portfolio will consist of four early-stage life sciences companies. Zoic believes Fund No.2 represents an opportunity for qualified investors to achieve curated exposure to the enhanced risks and rewards of life sciences venture investing.

Zoic has completed diligence on Fund No.2’s portfolio companies and is in the process of finalizing the term sheets which will govern the relationships between Zoic, Fund No.2, and the portfolio companies.


Juno Diagnostics has developed a diagnostic testing device capable of detecting the smallest possible number of DNA molecules in a human sample and producing an easy-to-read result in a one-step device, in a few minutes, at a cost of $10. Learn more

Prime Discoveries has created the leading AI system for linking disease states and therapies effectiveness with microbes. It is the only system backed by clinical evidence that links findings in the microbiome with specific conditions. Learn more

Neuraura has developed a implanted brain sensor, 20x more sensitive and accurate than current devices. This enables much more precise diagnosis and therapies of multiple brain conditions, such as epilepsy, Parkinson’s and depression. Learn more

OnCo is a for-profit spinout from the prestigious nonprofit Infectious Disease Research Institute (IDRI). IDRI has developed innovations for delivering targeted medical treatment to specific cells within the body through developed adjuvants. Learn more